Why has the Novo-share been skyrocketing in the last couple of days?
That‘s the question posed – and answered – by Danish bank Nordea in a new memo. The unanimous advice of stock market analysts is not to sell.
The pharmaceutical flagship Novo Nordisk has rarely been creating as much buzz as it is at the moment. The stock market is alive with enthusiasm, and it is mainly the candidate drug against obesity that is the talk of the town.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
